Skip to content

Does the Cap Increase the Finding of Polyps When Water Exchange Colonoscopy is Used

Does the Addition of a Cap Improve the Adenoma Detection Rate During Water Exchange Colonoscopy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03566615
Acronym
ASGE
Enrollment
1630
Registered
2018-06-25
Start date
2018-07-01
Completion date
2023-01-31
Last updated
2022-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonoscopy, Polyp of Colon

Keywords

colonoscopy, adenoma detection rate, caps

Brief summary

This is a study to compare two different, but normally, used methods of colonoscopy in patients that require a routine or repeat colonoscopy. There will be three arms in this study: WE water control, water plus Cap-1, and water plus Cap-2. The patient will prepare himself/herself for the colonoscopy as per normal instructions and he/she will be given the information for the study at that time so that he/she can make a decision to participate in the study. The control method will use water instead of air inserted into the colon. The study method will use a new accessory, a cap that will fit onto the end of the colonoscope plus water during the procedure. This study will also confirm if using the cap method with water is a better way of detecting polyps in the colon and possibly cancer.

Detailed description

This will be a multi-site, multi-national, unblinded investigators, prospective Random Control Trial (RCT). Randomization (WE, WE Cap-1, WE Cap-2) will be based on computer generated random numbers placed inside opaque sealed envelopes. The envelope (in pre-arranged order) will be opened to reveal the code when the colonoscopist is ready to insert the endoscope to begin the examination. This will be a comparison of two different methods with three arms (WE, WE Cap-1, WE Cap-2) to see which one is better at detecting adenomas. Patients who are willing to participate will sign an informed consent before starting the colonoscopy procedure. Separate parallel randomization will be set up at each site, stratified by investigator and type of colonoscopy (screening or surveillance). Mode of sedation will include unsedated (China, US West Los Angeles VA), minimally sedated (Taiwan), on demand sedation (Italy, Czech Republic, US West Los Angeles VA), conscious sedation (US Sacramento VA and Palo Alto VA) or full sedation with propofol (Taiwan). Randomization (prepared by statistics consultant) will be carried out by the method of random permuted block design (based on computer generated random numbers) with variable block sizes of 3 and 6. Gender will be used as a stratification factor. Control Method: One arm of the study will include sedated/unsedated colonoscopy with water (WE) as the control method. Residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion. Study method: The other two arms entail the addition of a simple commercially available accessory to the colonoscopy device: Cap -1 (Disposable Distal Attachment) or Cap-2, fitted to the colonoscope per manufacturer instruction. The two arms include sedated/unsedated colonoscopy with either a Cap-1 plus water or Cap-2 plus water.

Interventions

DEVICECAP-straight

This study is to detect any differences in the detection rate of adenomas using straight caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.

DEVICECAP-daisy

This study is to detect any differences in the detection rate of adenomas using daisy caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.

OTHERwater

using water instead of traditional air insufflation to help insertion

Sponsors

University of California, Los Angeles
CollaboratorOTHER
VA Greater Los Angeles Healthcare System
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. Male and female 50-75 yrs of age. 2. Positive screening for Fecal Immunochemical Test (FIT) or Fecal Occult Blood Test (FOBT). 3. Subjects willing to undergo routine screening and surveillance colonoscopy.

Exclusion criteria

1. Patients who decline to provide informed consent. 2. Patients known to have colonic obstruction, inflammatory bowel disease, or active GI bleeding requiring interventions. 3. Patients know to have prior history of severe diverticulitis/diverticulosis.

Design outcomes

Primary

MeasureTime frameDescription
Adenoma detection rate2 yearsThe proportion of individuals undergoing a complete screening colonoscopy who have one or more adenomas, or polyps, detected.

Secondary

MeasureTime frameDescription
Cecal intubation2 hours: Data collected during colonoscopy procedureVisualization of ileocecal valve/appendix orifice and the medial wall of the cecum with colonoscope tip touching floor of cecum
Boston bowel preparation score2 hours: Data collected during colonoscopy procedureThree segments (Right, transverse, left colon), each with 0 to 3 (poor to excellent); total scores = sum (10 point scale)
Cecal intubation time2 hours: Data collected during colonoscopy procedureTotal time from insertion into the anus to arrival in the cecum
Visual analogue scale (0=not satisfied, 10=very satisfied)2 hours: Data collected during colonoscopy procedurePatient satisfaction
Willing to repeat2 hours: Data collected during colonoscopy procedureVisual analogue scale (0=not willing, 10=willing)

Countries

China, Italy, Taiwan, United States

Contacts

Primary ContactVivek Dixit, PhD
vivek.dixit@va.gov818-895-9426
Backup ContactFelix W Leung, MD
Felix.Leung@va.gov818-891-7711

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026